Equities analysts expect that Ocular Therapeutix Inc (NASDAQ:OCUL) will report ($0.44) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Ocular Therapeutix’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.47). Ocular Therapeutix posted earnings of ($0.42) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 4.8%. The firm is expected to announce its next quarterly earnings report on Thursday, March 5th.

On average, analysts expect that Ocular Therapeutix will report full year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($1.71) to ($1.60). For the next fiscal year, analysts expect that the business will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.50) to ($0.75). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. The company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $1.09 million. Ocular Therapeutix had a negative return on equity of 383.58% and a negative net margin of 3,141.58%.

Several equities analysts have commented on the company. ValuEngine downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $6.00 price target (down from $9.00) on shares of Ocular Therapeutix in a research note on Friday, November 15th. Zacks Investment Research cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Finally, Piper Jaffray Companies lowered their price objective on Ocular Therapeutix from $8.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Ocular Therapeutix currently has a consensus rating of “Hold” and a consensus target price of $8.67.

In related news, major shareholder Opaleye Management Inc. purchased 15,000 shares of Ocular Therapeutix stock in a transaction on Thursday, January 2nd. The shares were purchased at an average price of $4.35 per share, for a total transaction of $65,250.00. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 16.10% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its holdings in Ocular Therapeutix by 11.5% during the 3rd quarter. California State Teachers Retirement System now owns 64,606 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 6,667 shares during the last quarter. Creative Planning increased its holdings in shares of Ocular Therapeutix by 37.8% during the third quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,500 shares in the last quarter. Royal Bank of Canada raised its position in shares of Ocular Therapeutix by 36.2% during the second quarter. Royal Bank of Canada now owns 147,478 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 39,218 shares during the period. State Street Corp raised its position in shares of Ocular Therapeutix by 15.9% during the third quarter. State Street Corp now owns 672,896 shares of the biopharmaceutical company’s stock worth $2,046,000 after purchasing an additional 92,165 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Ocular Therapeutix by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,871,947 shares of the biopharmaceutical company’s stock worth $8,236,000 after purchasing an additional 234,360 shares in the last quarter. Hedge funds and other institutional investors own 48.01% of the company’s stock.

OCUL stock traded down $0.19 during midday trading on Friday, reaching $4.50. 54,791 shares of the stock were exchanged, compared to its average volume of 617,800. Ocular Therapeutix has a 52 week low of $2.35 and a 52 week high of $5.55. The company has a fifty day moving average price of $4.30 and a 200 day moving average price of $4.03. The company has a debt-to-equity ratio of 5.07, a current ratio of 6.33 and a quick ratio of 6.25. The stock has a market capitalization of $230.30 million, a PE ratio of -2.38 and a beta of 2.23.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.